April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 12, 2025 | 11:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit alleges securities fraud, company discontinues NTLA-3001 research and reduces workforce, potentially impacting investor confidence and stock performance.
The lawsuit and company's strategic shift suggest significant operational challenges, potential financial strain, and reduced investor trust, likely leading to negative short-term stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100